Prostate cancer Posts - Page 27 of 80 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Exercise, body composition and fatigue with androgen deprivation therapy

Exercise, body composition and fatigue with androgen deprivation therapy

Posted by on May 22, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine whether body composition (lean and fat mass) and exercise had an effect on fatigue levels in men treated with androgen deprivation therapy. The study concluded that fat mass was associated with fatigue, and an increase in lean mass due to exercise successfully reduced fatigue. Some background Androgen...

Read More

5 Things You Probably Didn’t Know About Your Adrenal Glands

5 Things You Probably Didn’t Know About Your Adrenal Glands

Posted by on Mar 15, 2018 in Benign prostatic hyperplasia, Blog, Breast cancer, Colorectal cancer, Coronary artery disease, Diabetes mellitus, Erectile dysfunction, Hodgkin's lymphoma, Hypertension, Infertility, Kidney stones, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer, Rheumatoid Arthritis, Stroke, Urinary incontinence, Urinary tract infection | 5 comments

The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...

Read More

Right To Try: Needed Legislation or Snake Oil?

Right To Try: Needed Legislation or Snake Oil?

Posted by on Mar 10, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 1 comment

Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process.  There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...

Read More

Biochemical relapse-free survival outcomes for intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB)

Biochemical relapse-free survival outcomes for intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB)

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell This study examined rates of biochemical relapse after using intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB) in men with low and intermediate stage prostate cancer. This study found that rates of biochemical relapse were low after treatment.  Some background...

Read More

Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.

Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to identify risk factors of recurrence after prostatectomy in high risk patients. Patients with more risk factors were more likely to experience disease recurrence at five years. Some background Prostatectomy is a treatment option for prostate cancer. The prostate tumor is surgically removed. There are several risk...

Read More

Does age matter? Enzalutamide or bicalutamide for mestastatic castration-resistant prostate cancer patients of different ages

Posted by on Feb 12, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) compared to bicalutamide (Casodex) in castration-resistant metastatic prostate cancer (cancer that does not respond to hormone therapy) patients in different age groups. This study concluded that enzalutamide improved outcomes for...

Read More

To Treat or Not To Treat Cancer: Medical Decision-making

To Treat or Not To Treat Cancer: Medical Decision-making

Posted by on Jan 28, 2018 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 16 comments

Cherry Hughes** is an active, energetic 75 year old, still working in the marketing and public relations profession in Great Britain.  Her life is filled with friends and fun.  “I love cooking and eating out.  I am deeply interested in politics.  I love music …I go to jazz clubs.  I love going to France …I have a little apartment...

Read More

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

Posted by on Jan 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the links between prostate specific antigen (PSA, a protein present in prostate cancer) and survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. This studty concluded that PSA response after cabazitaxel treatment is associated with improved...

Read More